Novel Agents Articles


  • Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.

    The androgen receptor is a transcription factor and validated therapeutic target for prostate cancer. Androgen deprivation therapy remains the gold standard treatment, but it is not curative, and eventually the disease will return as lethal castration-resistant prostate cancer.

    Published June 16, 2016
  • New agents for prostate cancer.

    The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has been revolutionized by the arrival of multiple novel agents in the past 2 years. Immunotherapy in the form of sipuleucel-T, androgen axis inhibitors, including abiraterone acetate and enzalutamide, a chemotherapeutic agent, cabazitaxel, and a radiopharmaceutical, radium-223, have all yielded incremental extensions of survival and have been recently approved.

    Published February 12, 2020
  • Novel agents for castration-resistant prostate cancer: Early experience and beyond.

    Androgen deprivation therapy is the initial treatment for men with advanced prostate cancer. Almost all these patients eventually develop progressive castration-resistant prostate cancer despite an initial favorable response.

    Published September 1, 2015
  • Salvage Therapy for Non-muscle-invasive Bladder Cancer: Novel Intravesical Agents.

    Bacillus Calmette-Guerin (BCG)-refractory high-grade non-muscle-invasive bladder cancer remains a challenging problem. Radical cystectomy is standard of care, but carries significant morbidity. Therefore, there is a need for effective treatments.

    Published December 2, 2019